$PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

2023 Q4 Form 10-Q Financial Statement

#000126246323000120 Filed on October 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $42.93K $39.40K $34.08K
YoY Change -1.36% 15.61% -13.7%
% of Gross Profit
Research & Development $2.179K $1.520K $3.271K
YoY Change 38.53% -53.53% 57.18%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $45.11K $40.92K $37.35K
YoY Change 0.04% 9.56% -10.17%
Operating Profit -$45.11K -$40.92K -$37.35K
YoY Change 0.04% 9.56% -10.08%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$45.11K -$40.92K -$37.35K
YoY Change 0.04% 9.56% -10.07%
Income Tax
% Of Pretax Income
Net Earnings -$45.11K -$40.92K -$37.35K
YoY Change 0.04% 9.56% -10.08%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$1.889K
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.77M shares 19.77M shares
Diluted Shares Outstanding 19.77M shares 19.77M shares 19.77M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.870K $360.00 $200.00
YoY Change 938.89% 80.0%
Cash & Equivalents $1.868K $355.00 $200.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.868K $355.00 $200.00
YoY Change 967.43% 77.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.868K $355.00 $200.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $1.868K $355.00 $200.00
YoY Change 967.43% 77.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $460.7K $425.7K $303.8K
YoY Change 36.24% 40.13% -51.36%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.717M $1.710M $1.694M
YoY Change 1.08% 0.94% 41.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.385M $2.338M $2.178M
YoY Change 7.27% 7.35% 8.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.385M $2.338M $2.178M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.385M $2.338M $2.178M
YoY Change 7.27% 7.35% 8.83%
SHAREHOLDERS EQUITY
Retained Earnings -$5.115M -$5.070M -$4.910M
YoY Change 3.23% 3.26% 3.73%
Common Stock $19.77K $19.77K $19.77K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.383M -$2.338M -$2.178M
YoY Change
Total Liabilities & Shareholders Equity $1.868K $355.00 $200.00
YoY Change 967.43% 77.5%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$45.11K -$40.92K -$37.35K
YoY Change 0.04% 9.56% -10.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.11K -$13.60K -$13.29K
YoY Change -5.69% 2.33% 45.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.62K $13.95K $13.23K
YoY Change 8.6% 5.43% 45.88%
NET CHANGE
Cash From Operating Activities -10.11K -$13.60K -$13.29K
Cash From Investing Activities 0.000 $0.00 $0.00
Cash From Financing Activities 11.62K $13.95K $13.23K
Net Change In Cash 1.510K $349.00 -$59.00
YoY Change -7650.0% -691.53% 47.5%
FREE CASH FLOW
Cash From Operating Activities -$10.11K -$13.60K -$13.29K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001350156
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-52365
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4395271
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 34075 Westbrook PO
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
1610-37th Street S.W
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Calgary
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
AB
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
T3C 3W2
CY2023Q3 dei City Area Code
CityAreaCode
403
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
850-4120
CY2023Q3 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19767698 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
355 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
355 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6 usd
CY2023Q3 us-gaap Assets
Assets
355 usd
CY2023Q2 us-gaap Assets
Assets
6 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
155668 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
158348 usd
CY2023Q3 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q2 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2338004 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2296736 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2338004 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2296736 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5069850 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5028931 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2337649 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
7714 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
2500 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1685 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1576 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1520 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3271 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
40919 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
37347 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40919 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-37347 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40919 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37347 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40919 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2337649 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2140464 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37347 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2177811 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40919 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-37347 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
30000 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
30000 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2680 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5942 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13599 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13289 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q3 paxh Proceeds From Issuance Of Liability For Unissued Shares
ProceedsFromIssuanceOfLiabilityForUnissuedShares
0 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13948 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13230 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
349 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-59 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200 usd
CY2023Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q3 paxh Conversion Of Accounts Payable And Accrued Liabilities Related Party To Promissory Note Related Party
ConversionOfAccountsPayableAndAccruedLiabilitiesRelatedPartyToPromissoryNoteRelatedParty
0 usd
CY2022Q3 paxh Conversion Of Accounts Payable And Accrued Liabilities Related Party To Promissory Note Related Party
ConversionOfAccountsPayableAndAccruedLiabilitiesRelatedPartyToPromissoryNoteRelatedParty
0 usd
CY2023Q3 paxh Conversion Of Advances Related Party To Promissory Note Related Party
ConversionOfAdvancesRelatedPartyToPromissoryNoteRelatedParty
0 usd
CY2022Q3 paxh Conversion Of Advances Related Party To Promissory Note Related Party
ConversionOfAdvancesRelatedPartyToPromissoryNoteRelatedParty
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40919 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13599 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2337649 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zIMc49eHR1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_864_zOZCfD5Fp6W3">Use of Estimates</span> </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1520 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3271 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 paxh Commissions Percentage
CommissionsPercentage
0.10 pure
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001262463-23-000120-index-headers.html Edgar Link pending
0001262463-23-000120-index.html Edgar Link pending
0001262463-23-000120.txt Edgar Link pending
0001262463-23-000120-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
paxh-20230831.xsd Edgar Link pending
paxh8312023q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
paxh-20230831_cal.xml Edgar Link unprocessable
paxh-20230831_def.xml Edgar Link unprocessable
paxh-20230831_lab.xml Edgar Link unprocessable
paxh-20230831_pre.xml Edgar Link unprocessable
paxh8312023q_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending